Regeneron Pharmaceuticals Inc to Share Updates on Hematology Portfolio Investor Event at ASH Transcript
Good day, and thank you for standing by. Welcome to Regeneron's ASH 2021 Investor Event Conference Call. (Operator Instructions) Please note that this conference is being recorded. (Operator Instructions)
And now, I'd like to hand the conference over to your first speaker today, Mark Hudson, from Investor Relations. Thank you. Please go ahead.
Thank you. Welcome, everyone, to Regeneron's Oncology/Hematology ASH 2021 Webcast. Joining me on the call today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Dr. Andres Sirulnik, Senior Vice President, Translational and Clinical Science, Hematology; Dr. Izzy Lowy, Senior Vice President of Translational and Science in Oncology. After our prepared remarks, we'll open up the call for Q&A.
Before handing the call over to George, I'd like to remind you that remarks made today include forward-looking statements about Regeneron, including those related to Regeneron's business and research and development programs,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |